Last updated: September 8, 2026
Eculizumab is a high-value complement C5 inhibitor marketed primarily as Soliris by Alexion, an AstraZeneca company. Its commercial base remains substantial, but the product is in a managed transition: Soliris revenue is declining as patients move to the longer-acting successor Ultomiris, while direct biosimilar pressure remains limited in the United States and Europe as of June 2024. AstraZeneca’s eculizumab franchise is protected less by the original composition patent than by clinical switching, orphan-drug positioning, manufacturing complexity, and the commercial expansion of ravulizumab.
What is eculizumab and which products compete with it?
Eculizumab is a recombinant humanized monoclonal antibody that binds complement protein C5 and blocks terminal complement activation. Soliris is administered intravenously and is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder in the United States.[1]
The principal competitive product is ravulizumab, marketed as Ultomiris. Ravulizumab is an engineered successor to eculizumab with an extended half-life, allowing less frequent administration. It is approved in several of the same indications and is being used to migrate patients away from Soliris.[2]
| Product |
Active ingredient |
Developer/owner |
Core mechanism |
Commercial role |
| Soliris |
Eculizumab |
Alexion, AstraZeneca |
C5 inhibition |
Original franchise product |
| Ultomiris |
Ravulizumab |
Alexion, AstraZeneca |
Long-acting C5 inhibition |
Primary growth and switching product |
| Empaveli |
Pegcetacoplan |
Apellis |
C3 inhibition |
Alternative PNH therapy |
| Iptacopan |
Iptacopan |
Novartis |
Factor B inhibition |
Oral alternative in PNH |
| Crovalimab |
Crovalimab |
Roche |
Long-acting C5 inhibition |
Emerging subcutaneous C5 competitor |
The market is shifting from a single-product C5 franchise toward differentiated administration, dosing frequency, route of administration, and payer economics. Oral and subcutaneous complement inhibitors have a greater potential impact than traditional intravenous antibodies because they can reduce infusion burden and improve patient convenience.
How large is the eculizumab and C5 inhibitor market?
The addressable market consists of rare complement-mediated diseases with high treatment costs and limited alternatives. PNH and aHUS historically generated the largest Soliris revenue pools, while generalized myasthenia gravis and NMOSD expanded the addressable population.
Eculizumab is one of the highest-priced biologics. Treatment economics vary by indication, patient weight, dosing schedule, geography, negotiated rebates, and hospital or specialty-pharmacy procurement. Published U.S. estimates have placed annual Soliris treatment costs in the hundreds of thousands of dollars per patient, with some treatment regimens exceeding $500,000 before rebates and discounts.[3]
Commercial demand is supported by:
- Severe diseases with high unmet need.
- Long-term or lifelong treatment in many patients.
- Limited therapeutic substitutes in complement-mediated disease.
- Orphan-drug reimbursement systems.
- High switching costs for physicians and patients.
- Clinical value from preventing hemolysis, thrombosis, renal injury, or disability.
The main market constraints are high payer scrutiny, budget impact, vaccination and infection-management requirements, and the emergence of lower-frequency or nonintravenous alternatives.
What is the revenue trajectory for Soliris and Ultomiris?
Soliris revenue has entered structural decline because AstraZeneca is deliberately moving patients to Ultomiris. This is a lifecycle-management strategy rather than a simple loss of demand for C5 inhibition.
AstraZeneca reported the following broad commercial pattern in its annual reporting:
| Period |
Soliris trajectory |
Ultomiris trajectory |
Main driver |
| 2020 |
Approximately $4.1 billion in sales |
Early commercial expansion |
Established Soliris franchise |
| 2021 |
Declining after AstraZeneca acquisition |
Rapid growth |
Patient conversion and broader launch |
| 2022 |
Continued decline |
Strong double-digit growth |
Longer-acting dosing and indication expansion |
| 2023 |
Further decline |
Approximately $3.1 billion in reported sales |
Ongoing conversion from Soliris |
| 2024 onward |
Expected erosion |
Primary franchise growth engine |
New indications and continued switching |
AstraZeneca’s Alexion unit generated more than $8 billion in 2023 revenue across Soliris, Ultomiris, Strensiq, Kanuma, and other rare-disease products. Ultomiris became the central commercial asset within the complement portfolio, while Soliris remained important for patients who were clinically stable, had established access, or were not immediately switched.[4]
The revenue trajectory has three phases:
Phase one: Soliris dominance
Before Ultomiris reached scale, Soliris was the leading commercial C5 inhibitor. Its high price and chronic use produced strong revenue despite a small patient population.
Phase two: internal cannibalization
Ultomiris reduced Soliris sales by replacing the older product in PNH and aHUS. The transition protected franchise revenue because patients generally remained within AstraZeneca’s C5 portfolio.
Phase three: external competition
The next risk is competition from oral factor B inhibitors, C3 inhibitors, subcutaneous C5 inhibitors, and eculizumab biosimilars. The effect will depend on comparative outcomes, dosing convenience, payer contracting, and regulatory interchangeability.
When does eculizumab lose exclusivity?
The original U.S. composition patent for eculizumab, U.S. Patent No. 6,355,245, expired in 2021 after adjustment and pediatric considerations were taken into account. That date ended the strongest composition-of-matter barrier to direct competition.[5]
Patent expiry did not immediately produce U.S. biosimilar entry. For biologics, regulatory exclusivity, patent litigation, manufacturing readiness, clinical comparability, and commercial launch economics all affect the timing of competition.
Key exclusivity milestones include:
| Milestone |
Approximate timing |
Commercial significance |
| First U.S. approval of Soliris for PNH |
2007 |
Created the initial orphan franchise |
| PNH orphan exclusivity |
2007-2014 |
Blocked approval of the same orphan indication |
| aHUS approval |
2011 |
Added a major chronic-use market |
| Pediatric exclusivity |
Added six months where applicable |
Extended certain regulatory protections |
| gMG approval |
2017 |
Expanded the addressable population |
| NMOSD approval |
2019 |
Added another specialty indication |
| Original composition patent expiry |
2021 |
Removed the principal molecule patent barrier |
| Post-2021 period |
2021 onward |
Patent, litigation, manufacturing, and market-entry barriers became more important |
The exact launch date for a competing biologic depends on patent settlements, regulatory approval, manufacturing capacity, and commercial strategy. Patent expiry alone does not establish an immediate unrestricted launch date.
What patents protect eculizumab and Soliris?
The foundational patent estate protected the eculizumab antibody and its use in complement-mediated disease. The original composition patent is no longer the primary barrier in the United States. Remaining protection has historically involved:
- Method-of-use claims for PNH, aHUS, gMG, and NMOSD.
- Dosing regimens and treatment protocols.
- Patient-selection claims.
- Formulation and stability claims.
- Manufacturing and purification processes.
- Device, container, and administration claims.
- Patent families covering ravulizumab and the Ultomiris product lifecycle.
Biologic patent analysis requires reviewing the FDA Purple Book, USPTO records, international patent registers, and court dockets. The Purple Book identifies reference biological products and biosimilar relationships, but it does not replicate the small-molecule Orange Book framework.[6]
How strong is the remaining eculizumab patent estate?
The remaining estate is materially weaker than a live composition patent because use and formulation patents can often be designed around. Its practical strength depends on:
- Whether a competing product seeks the same indications.
- Whether the competitor uses the same dosing schedule.
- Whether the reference sponsor asserts formulation or manufacturing claims.
- Whether the biosimilar applicant uses a confidential alternative process.
- Whether the product is launched for a non-patent-blocked indication.
A biosimilar applicant can challenge patents through the Biologics Price Competition and Innovation Act process, including a patent dance and Paragraph IV-style certifications. Unlike small-molecule generics, biologic applicants do not rely on an Orange Book certification structure in the same way. The legal analysis is patent-specific and depends on the product, filing strategy, and asserted claims.[7]
What is the Orange Book and Purple Book status of eculizumab?
Soliris is a biologic, so its core regulatory reference is the FDA Purple Book rather than the Orange Book. The Orange Book primarily covers approved small-molecule drugs and their listed patents. The Purple Book identifies the reference product, biosimilar products, interchangeable biosimilars, exclusivity information, and related biologic status.[6]
For market-access purposes, the relevant questions are:
- Is a product licensed as a biosimilar to Soliris?
- Has it received an interchangeable designation?
- Which reference-product exclusivity periods remain?
- Which patents could support an injunction or damages claim?
- Has the applicant provided a notice of commercial marketing?
- Is the competing product approved for all or only some Soliris indications?
As of June 2024, no FDA-approved eculizumab biosimilar had established a broad U.S. commercial presence comparable to the reference product. The principal competitive threat was therefore lifecycle substitution to Ultomiris and emerging alternative complement inhibitors.
Which companies are challenging the Soliris franchise?
The competitive landscape includes both direct and indirect challengers.
Direct eculizumab biosimilar developers
Several global biologics companies have evaluated eculizumab biosimilar programs, but development status and launch timing differ by jurisdiction. The critical commercial issue is whether a candidate can demonstrate comparable pharmacokinetics, pharmacodynamics, immunogenicity, and clinical performance while achieving meaningful price reduction.
Roche
Roche’s crovalimab is a long-acting C5 inhibitor designed for less frequent administration and subcutaneous delivery. Its commercial value proposition is convenience and reduced infusion dependence rather than molecule-for-molecule substitution.[8]
Novartis
Iptacopan is an oral factor B inhibitor. It competes at an earlier point in the alternative pathway and can reduce reliance on intravenous terminal-pathway antibodies. The product’s risk profile includes the possibility that physicians and payers will favor oral administration in appropriate patients.[9]
Apellis
Pegcetacoplan, marketed as Empaveli for PNH, inhibits complement component C3. It offers a different mechanism and subcutaneous administration, but its positioning depends on efficacy, safety, breakthrough hemolysis, and treatment convenience.[10]
AstraZeneca
AstraZeneca is both the incumbent and the most significant internal competitor to Soliris through Ultomiris. The company has used the successor product to preserve C5 franchise revenue while reducing exposure to future Soliris erosion.
What biosimilar risk exists for eculizumab?
Eculizumab has meaningful long-term biosimilar risk, but the risk is moderated by several factors.
Clinical switching risk
Patients with PNH and aHUS may remain on a well-controlled therapy because breakthrough hemolysis or complement-mediated disease recurrence can have severe consequences. Physicians may prefer a product with a long safety record unless the biosimilar demonstrates strong clinical comparability.
Manufacturing risk
Eculizumab is a complex monoclonal antibody produced through mammalian-cell culture and multistage purification. A biosimilar manufacturer must match critical quality attributes, including glycosylation, aggregation, charge variants, potency, purity, and immunogenicity. Process differences can increase development cost and regulatory risk.
Commercial pricing risk
A biosimilar may need a substantial discount to overcome physician and payer friction. The market may also be divided between low-price biosimilar competition and premium products offering less frequent or subcutaneous dosing.
Interchangeability risk
An interchangeable designation can accelerate pharmacy-level substitution where permitted, but it does not guarantee rapid uptake in specialty biologics. Infusion-center protocols, specialist control, payer formularies, and patient stability remain important.
What formulation and method-of-use patents protect the franchise?
Formulation and method-of-use patents can delay competition after the foundational molecule patent expires, but their scope is generally narrower.
Relevant claim categories include:
- Intravenous formulations with defined concentrations and excipients.
- Storage and stability conditions.
- Specific dosing intervals.
- Treatment of patients with complement-mediated disease.
- Maintenance regimens following induction.
- Use in patients with renal failure or other defined clinical characteristics.
- Combination or vaccination-management protocols.
These patents can support litigation against a biosimilar applicant if the proposed label, formulation, or manufacturing process practices the asserted claims. They are less likely to provide the same exclusionary power as a broad composition patent.
What patent litigation and settlement risks affect eculizumab?
The highest litigation risk arises when a biosimilar applicant seeks approval before the reference sponsor’s commercial protection has fully expired. Potential claims may involve formulation, therapeutic use, dosing, manufacturing, or antibody characterization.
Possible outcomes include:
- Immediate launch after regulatory approval.
- Launch before all asserted patents expire under a negotiated license.
- A delayed-entry settlement.
- A launch limited to non-patented indications.
- Litigation followed by an injunction or damages award.
- A commercial agreement allowing entry at a defined date.
AstraZeneca’s acquisition of Alexion transferred control of the Soliris and Ultomiris franchise to a larger company with the resources to defend patents, negotiate settlements, and manage global pricing. The transaction was valued at approximately $39 billion and closed in July 2021.[11]
How does Soliris compare with Ultomiris?
| Factor |
Soliris |
Ultomiris |
| Molecule |
Eculizumab |
Ravulizumab |
| Target |
C5 |
C5 |
| Dosing frequency |
More frequent intravenous dosing |
Less frequent dosing |
| Market position |
Mature and declining |
Growth product |
| Patent position |
Older estate with foundational expiry |
Newer lifecycle estate |
| Commercial objective |
Retain established patients |
Convert and expand patients |
| Biosimilar exposure |
Direct eculizumab risk |
Separate ravulizumab risk |
| Payer value proposition |
Proven efficacy and safety |
Lower administration burden |
Ultomiris gives AstraZeneca time to defend the franchise against eculizumab biosimilars. However, the strategy also creates a new long-term patent and pricing cycle for ravulizumab. If payers treat Soliris biosimilars as interchangeable with Ultomiris for some patients, AstraZeneca could face pressure across both products.
What generic launch scenarios exist for eculizumab?
The most likely scenarios are:
Scenario one: gradual specialty uptake
One or more biosimilars enter with a moderate discount. Adoption is slow because physicians maintain stable patients on Soliris or switch them to Ultomiris.
Scenario two: payer-driven conversion
Insurers and national health systems designate a biosimilar as preferred. New starts move rapidly to the lower-cost product, while existing patients transition under utilization-management protocols.
Scenario three: limited indication launch
A biosimilar launches only for indications with less complex patent exposure. The competitor avoids certain method-of-use claims and competes selectively in PNH or aHUS.
Scenario four: non-antibody displacement
Oral factor B inhibition, C3 inhibition, or subcutaneous C5 inhibition captures share before eculizumab biosimilars reach scale. This would weaken the economic value of the Soliris reference product even without direct molecule competition.
What is the geographic coverage of eculizumab protection?
Eculizumab has been commercialized across major pharmaceutical markets, including the United States, European Union, Japan, and other regulated markets. Patent expiry and biosimilar timing differ by country. Europe generally has earlier biosimilar access dynamics than the United States, while national health systems apply stronger price controls and tendering.
Commercial exposure varies by region:
- The United States has high per-patient revenue and significant payer concentration.
- Europe has stronger health-technology assessment and price-negotiation pressure.
- Japan has a smaller but strategically important rare-disease market.
- Emerging markets may have lower prices, local manufacturing initiatives, and weaker enforcement of secondary patents.
What manufacturing barriers limit eculizumab competition?
Manufacturing is a meaningful barrier because biosimilar developers must reproduce a complex biologic through an independent process. Key requirements include:
- Validated mammalian-cell production.
- Consistent glycosylation and molecular structure.
- High-purity downstream processing.
- Viral clearance and contamination control.
- Sterile fill-finish capacity.
- Cold-chain distribution.
- Pharmacovigilance for immunogenicity and serious infection risk.
The clinical use of C5 inhibitors also creates operational requirements. Patients require meningococcal vaccination or other risk-management measures because terminal complement inhibition increases susceptibility to invasive meningococcal disease. This adds treatment infrastructure beyond the antibody itself.[1]
Key Takeaways
- Soliris is a mature eculizumab franchise product with declining revenue as patients move to Ultomiris.
- Ultomiris is AstraZeneca’s primary growth engine in terminal complement inhibition.
- The foundational U.S. eculizumab composition patent expired in 2021.
- Direct biosimilar risk remains constrained by manufacturing complexity, specialist prescribing, safety concerns, and the availability of newer complement inhibitors.
- The FDA regulatory reference is the Purple Book, not the Orange Book.
- Formulation and method-of-use patents can support litigation but generally provide narrower protection than a composition patent.
- Roche, Novartis, and Apellis are important non-biosimilar competitors.
- The largest commercial risk is a combination of payer-driven biosimilar substitution and migration to oral or subcutaneous complement therapies.
- AstraZeneca’s acquisition of Alexion created a stronger balance sheet and broader commercial platform for franchise defense.
- Eculizumab remains financially important, but future growth depends primarily on the broader complement portfolio rather than Soliris alone.
FAQs about eculizumab market and patent risk
Is eculizumab still commercially important after the 2021 patent expiry?
Yes. Soliris remains important because patients require chronic therapy, specialist physicians value its established safety record, and AstraZeneca controls a broader C5 franchise through Ultomiris.
Can a biosimilar launch after the eculizumab composition patent expires?
Yes, but regulatory approval does not automatically eliminate method-of-use, formulation, manufacturing, settlement, or market-access barriers.
Is Ultomiris a biosimilar to Soliris?
No. Ultomiris is a separate engineered antibody, ravulizumab, developed by Alexion as a longer-acting successor to eculizumab.
Which eculizumab indication has the greatest commercial value?
PNH and aHUS have historically been core revenue drivers because they require chronic complement inhibition and involve high disease burden. Generalized myasthenia gravis and NMOSD expanded the market.
Will oral complement inhibitors replace eculizumab?
They can take share in appropriate patients, particularly when oral administration reduces infusion burden. Replacement will depend on comparative efficacy, safety, breakthrough disease, reimbursement, and physician confidence.
Sources
- U.S. Food and Drug Administration. (2024). Soliris prescribing information.
- U.S. Food and Drug Administration. (2024). Ultomiris prescribing information.
- Institute for Clinical and Economic Review. (2020). Final evidence report: Treatments for paroxysmal nocturnal hemoglobinuria.
- AstraZeneca. (2024). Annual report and Form 20-F for the year ended December 31, 2023.
- U.S. Patent and Trademark Office. (2024). U.S. Patent No. 6,355,245 patent records.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009.
- Roche. (2024). Crovalimab clinical development and regulatory information.
- Novartis. (2024). Fabhalta prescribing information and regulatory materials.
- Apellis Pharmaceuticals. (2024). Empaveli prescribing information.
- AstraZeneca. (2021). AstraZeneca completes acquisition of Alexion.
